A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Phase 1 Completed 42 enrolled Cue Biopharma

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Timeline

Start: 2022-06-14
Primary completion: 2025-03-12
Completion: 2025-03-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CUE-102	Protein / enzyme biologic	1 mg/kg	Intravenous
Subject	CUE-102	Protein / enzyme biologic	2 mg/kg	Intravenous
Subject	CUE-102	Protein / enzyme biologic	4 mg/kg	Intravenous
Subject	CUE-102	Protein / enzyme biologic	8 mg/kg	Intravenous

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Summary

Timeline

Drugs

Indications